Repare Therapeutics (NASDAQ:RPTX) Price Target Cut to $5.00 by Analysts at HC Wainwright

Repare Therapeutics (NASDAQ:RPTX) had its price target reduced by HC Wainwright from $10.00 to $5.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also recently issued reports about the company. Lifesci Capital reissued a “market perform” rating on shares of Repare Therapeutics in a report on Friday, December 13th. Bloom Burton cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 10th. Finally, Stifel Nicolaus dropped their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 13th.

Repare Therapeutics Trading Down 0.4 %

Shares of NASDAQ RPTX opened at $1.19 on Friday. The company has a market capitalization of $50.38 million, a P/E ratio of -0.59 and a beta of 0.87. The stock has a 50 day moving average of $1.25 and a 200-day moving average of $2.42. Repare Therapeutics has a 12 month low of $1.06 and a 12 month high of $6.08.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. Repare Therapeutics had a negative return on equity of 40.87% and a negative net margin of 99.76%. Analysts predict that Repare Therapeutics will post -2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Repare Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RPTX. Stifel Financial Corp raised its holdings in Repare Therapeutics by 36.4% in the 3rd quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after acquiring an additional 13,800 shares in the last quarter. Barclays PLC raised its holdings in shares of Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after buying an additional 7,800 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in shares of Repare Therapeutics by 45.8% during the 4th quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after buying an additional 11,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Repare Therapeutics by 2,144,950.0% during the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock worth $112,000 after buying an additional 85,798 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Repare Therapeutics by 204.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock worth $45,000 after buying an additional 23,127 shares in the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.